Doxycycline is a broad-spectrum belonging to the class, widely used in the treatment of various bacterial and protozoal infections. It functions by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit, thereby preventing microbial replication [1]. Its clinical applications span a wide range of conditions, including , , such as chlamydia and syphilis, like acne and rosacea, and rickettsial diseases such as Rocky Mountain spotted fever and Lyme disease [2]. Additionally, doxycycline is employed in the prophylaxis of diseases like in endemic regions, , and increasingly, as post-exposure prophylaxis for bacterial sexually transmitted infections (STIs) in high-risk populations [3]. Administered primarily orally, it has high bioavailability and excellent tissue penetration, reaching therapeutic concentrations in the lungs, prostate, eyes, and central nervous system [4]. However, its use is associated with notable side effects, including gastrointestinal disturbances, photosensitivity, and contraindications in children under 8 years, pregnant women, and nursing mothers due to risks of tooth discoloration and bone development issues [5]. The rise of antimicrobial resistance, particularly among STI-causing pathogens, underscores the importance of rational use guided by clinical guidelines from organizations such as the and the [6]. Furthermore, significant drug interactions—such as reduced absorption with calcium, iron, or magnesium-containing products and potential potentiation of —necessitate careful patient counseling and monitoring [7].
Mechanism of Action and Pharmacokinetics
Doxycycline exerts its antibacterial effects primarily through the inhibition of protein synthesis in susceptible microorganisms. As a member of the class, it achieves this by reversibly binding to the 30S ribosomal subunit of bacterial ribosomes [5]. This binding prevents the attachment of aminoacyl-tRNA to the acceptor site (A-site) on the ribosome, thereby halting the elongation of the peptide chain during protein translation [9]. The resulting blockade of essential protein production impairs bacterial growth and replication, leading to a bacteriostatic effect—meaning it inhibits bacterial proliferation without necessarily killing the organisms outright [4]. In high concentrations, doxycycline may exhibit bactericidal activity, potentially through mechanisms such as chelation of essential metal ions like magnesium and iron, which are cofactors for critical bacterial enzymes [11].
Pharmacokinetic Profile and Tissue Distribution
Following oral administration, doxycycline demonstrates high and predictable bioavailability, ranging from 90% to 100%, ensuring efficient systemic absorption from the gastrointestinal tract [2][4]. Its pharmacokinetic advantages include a prolonged elimination half-life of approximately 12 to 22 hours, which permits convenient once- or twice-daily dosing regimens and enhances patient adherence to treatment [4]. This extended half-life is a significant improvement over earlier tetracyclines, contributing to its widespread clinical use.
A key factor in doxycycline’s therapeutic efficacy is its high lipophilicity, which facilitates excellent penetration across biological membranes and widespread distribution into tissues and body fluids [5]. It achieves effective concentrations in critical sites such as the lungs, prostate, eyes, liver, and even the central nervous system [4]. This broad tissue distribution is particularly advantageous for treating intracellular pathogens such as Chlamydia trachomatis, Rickettsia spp., Mycoplasma pneumoniae, and Borrelia burgdorferi, which reside within host cells and require antibiotics capable of crossing cellular barriers [17][18].
Elimination and Metabolic Considerations
Doxycycline is eliminated through multiple pathways, with a significant portion excreted unchanged in the urine via glomerular filtration and in the feces through biliary and intestinal excretion [4][20]. Unlike many other antibiotics, doxycycline does not require dose adjustment in patients with renal impairment, as it is less dependent on renal clearance compared to other tetracyclines [21]. This property makes it a preferred choice in patients with compromised kidney function. Similarly, in cases of hepatic insufficiency, dose modification is generally not required, although cautious use and monitoring are advised due to the drug’s partial hepatic metabolism and potential for rare hepatotoxicity [21][23]. The ability to avoid dose adjustments in both renal and hepatic disease enhances its utility in elderly patients and those with comorbidities.
Clinical Implications of Pharmacokinetic Properties
The favorable pharmacokinetic profile of doxycycline—characterized by high oral bioavailability, prolonged half-life, and extensive tissue penetration—underpins its role as a first-line agent in various infections. These properties are especially beneficial in treating vector-borne and zoonotic diseases such as , , and , where pathogen localization within cells and deep tissues demands effective intracellular antibiotic concentrations [24]. Furthermore, its reliable absorption allows for oral administration even in outpatient settings, reducing the need for intravenous therapy in many cases [25]. However, absorption can be significantly impaired by divalent and trivalent cations such as calcium, magnesium, aluminum, and iron, which form insoluble chelates with doxycycline in the gastrointestinal tract [26]. Therefore, patients should avoid concomitant intake of dairy products, antacids, or mineral supplements within two to six hours of dosing to ensure optimal therapeutic levels [2].
Approved and Off-Label Therapeutic Uses
Doxycycline is a broad-spectrum belonging to the class, with a wide range of approved and off-label indications due to its unique pharmacokinetic and pharmacodynamic properties. Its clinical utility spans numerous infectious and inflammatory conditions, supported by guidelines from organizations such as the and the . The drug’s ability to achieve high tissue concentrations and its activity against intracellular pathogens make it a preferred choice in many clinical scenarios.
Approved Therapeutic Uses
Doxycycline is formally approved for the treatment of a diverse array of bacterial infections. These include respiratory tract infections such as pneumonia and bronchitis caused by susceptible organisms like Haemophilus influenzae and Mycoplasma pneumoniae [2]. It is also indicated for genitourinary infections, particularly those caused by Chlamydia trachomatis, Ureaplasma, and Mycoplasma species, making it a first-line agent for non-gonococcal urethritis [11].
In the realm of sexually transmitted infections (STIs), doxycycline is a cornerstone therapy for chlamydia, gonorrhea (in combination regimens), syphilis (as an alternative in penicillin-allergic patients), and infections caused by Mycoplasma genitalium [6]. For skin infections, it is approved for moderate to severe acne and rosacea, where its anti-inflammatory properties complement its antimicrobial effects [25].
Doxycycline is the treatment of choice for rickettsial diseases, including Rocky Mountain spotted fever, typhus, and rickettsiosis, due to its excellent penetration into endothelial cells where these obligate intracellular bacteria reside [32]. It is also indicated for early-stage Lyme disease, ocular infections such as chlamydial conjunctivitis, and certain intra-abdominal and urinary tract infections in specific clinical contexts [4].
Additionally, doxycycline is approved for the prophylaxis of several diseases. It is widely used for malaria prevention in chloroquine-resistant regions, particularly in travelers to sub-Saharan Africa and Southeast Asia [11]. It is also recommended for leptospirosis and cholera prophylaxis in high-risk exposure situations, such as during natural disasters or occupational hazards [35].
Off-Label Therapeutic Uses
Beyond its approved indications, doxycycline is frequently used off-label based on strong clinical evidence and expert consensus. One of the most significant off-label applications is post-exposure prophylaxis for bacterial STIs (DoxyPEP). Studies have shown that a single 200 mg dose of doxycycline administered within 72 hours of high-risk sexual exposure significantly reduces the incidence of chlamydia, gonorrhea, and syphilis in populations such as men who have sex with men (MSM) and individuals living with HIV [3]. This strategy has been evaluated by health authorities like CONITEC in Brazil and is increasingly integrated into public health programs, though concerns about antimicrobial resistance necessitate careful implementation.
Another well-established off-label use is in periodontal disease. At a subantimicrobial dose of 40 mg daily, doxycycline inhibits matrix metalloproteinases (MMPs), enzymes that degrade connective tissue in the gums, thereby reducing inflammation and slowing the progression of chronic periodontitis [37]. This use leverages the drug’s anti-inflammatory rather than antimicrobial properties, minimizing the risk of resistance.
Doxycycline is also used off-label for rosacea, particularly in its inflammatory forms. Low-dose regimens help control papules and pustules by modulating the immune response and reducing inflammatory mediators [11]. Its efficacy in this condition is supported by clinical trials and dermatological guidelines.
Clinical Advantages and First-Line Indications
Doxycycline is considered first-line therapy in several critical conditions. It is the preferred treatment for rickettsioses, including Rocky Mountain spotted fever and Brazilian spotted fever, with early administration significantly reducing mortality [39]. Similarly, it is a first-line option for chlamydial infections, with a 7-day course of 100 mg twice daily showing superior efficacy to single-dose azithromycin, especially in rectal infections [40].
In atypical pneumonia caused by Mycoplasma pneumoniae or Chlamydophila pneumoniae, doxycycline is a recommended first-line agent, particularly in adults and children over 8 years, due to rising macrolide resistance [41]. It is also essential in treating ehrlichiosis and anaplasmosis, tick-borne diseases where its intracellular penetration is crucial [24].
For brucellosis, doxycycline is a key component of combination therapy, typically paired with rifampicin or an aminoglycoside, and is part of updated treatment protocols in the Brazilian Unified Health System (SUS) [43].
Use in Multidrug-Resistant Infections
Doxycycline has emerged as a valuable alternative in infections caused by multidrug-resistant (MDR) bacteria. It shows in vitro activity against many MDR Gram-negative pathogens, including carbapenem-resistant Acinetobacter baumannii (CRAB) and some MDR Escherichia coli strains [44]. Its oral bioavailability and low toxicity profile make it a practical option for step-down therapy or long-term management, reducing reliance on more toxic agents like colistin.
It is also used in skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA), particularly in outpatient settings, where it offers good tissue penetration and tolerability [9].
In summary, doxycycline's versatility stems from its broad-spectrum activity, favorable pharmacokinetics, and dual antimicrobial and anti-inflammatory effects. Its role extends from first-line therapy in life-threatening rickettsial diseases to innovative off-label applications like DoxyPEP and periodontal management. However, its expanding use, particularly in prophylaxis, underscores the need for vigilant antimicrobial stewardship to preserve its efficacy in the face of growing resistance [46].
Dosage, Administration, and Treatment Duration
Doxycycline is administered primarily via the oral route, with formulations including tablets, capsules, and dispersible tablets, and in severe cases, it may be given intravenously [25]. The dosing regimen varies significantly depending on the type and severity of the infection, patient age, and clinical context. A common standard dose for adults is 100 mg once or twice daily, with an initial loading dose of 200 mg on the first day in certain indications to achieve rapid therapeutic concentrations [48]. This dosing flexibility is supported by its prolonged half-life, which ranges from 12 to 22 hours, allowing for convenient once- or twice-daily administration and enhancing patient adherence to treatment regimens [4].
Adult and Pediatric Dosing Guidelines
For adults, the typical dosage for most bacterial infections is 100 mg twice daily or 200 mg as a single daily dose. In the treatment of sexually transmitted infections (STIs) such as chlamydia, a regimen of 100 mg twice daily for 7 days is recommended, with evidence suggesting superiority over single-dose azithromycin, particularly for asymptomatic rectal infections [40]. For syphilis in penicillin-allergic non-pregnant adults, 100 mg twice daily for 14 days is an accepted alternative therapy [51]. In rickettsial diseases such as Rocky Mountain spotted fever and Brazilian spotted fever, doxycycline is the treatment of choice, with a dose of 100 mg every 12 hours for 7 to 10 days, or until 3 days after fever resolution [39].
In pediatric patients, doxycycline is generally contraindicated in children under 8 years of age due to the risk of permanent tooth discoloration and impaired bone development [4]. However, exceptions are made for life-threatening infections such as rickettsioses, anthrax, and severe malaria, where the benefits outweigh the risks [54]. For children over 8 years or weighing more than 45 kg, the adult dosing regimen is typically followed. For younger children in approved indications, the dose is 2.2 mg/kg every 12 hours, not exceeding a maximum daily dose of 200 mg [2].
Specialized Dosing for Dermatological and Anti-inflammatory Use
Doxycycline is used in dermatology at different dose levels depending on the condition. For moderate to severe acne vulgaris, a bacteriostatic dose of 100 mg once or twice daily is standard, typically for a limited duration of 3 to 4 months to minimize the risk of antimicrobial resistance [56]. In contrast, for the treatment of inflammatory rosacea, a subantimicrobial dose of 40 mg once daily, formulated for modified release, is used to achieve anti-inflammatory effects without significant antibacterial activity [57]. This approach inhibits matrix metalloproteinases and pro-inflammatory cytokines, reducing papules and pustules while minimizing the selection of resistant bacteria [58]. The use of low-dose doxycycline allows for long-term maintenance therapy with a more favorable safety profile.
Prophylactic and Post-Exposure Dosing Regimens
Doxycycline is employed in various prophylactic settings. For malaria prevention in travelers to endemic regions, a dose of 100 mg daily is recommended, starting 1 to 2 days before travel, continuing throughout the stay, and for 4 weeks after departure from the risk area [59]. This regimen is particularly effective in areas with chloroquine-resistant Plasmodium falciparum. For leptospirosis prophylaxis in high-risk populations during floods or disasters, a weekly dose of 200 mg is used [60]. More recently, doxycycline has been adopted for post-exposure prophylaxis of bacterial STIs (DoxPEP), with a single 200 mg dose administered within 72 hours of a high-risk sexual exposure, significantly reducing the incidence of chlamydia, gonorrhea, and syphilis in key populations such as men who have sex with men and people living with HIV [3].
Administration Considerations and Duration of Therapy
To optimize absorption and minimize adverse effects, doxycycline should be taken with a full glass of water to prevent esophageal irritation and ulceration [62]. Patients should remain upright for at least 30 minutes after ingestion. While food can slightly reduce absorption, it is often recommended to take the medication with a light meal to mitigate gastrointestinal side effects such as nausea and vomiting, especially in sensitive individuals [25]. The duration of therapy is tailored to the infection; for example, 7 days for chlamydia, 7 to 10 days for rickettsial infections, and up to 4 weeks for malaria prophylaxis. In long-term dermatological use, treatment duration is limited to reduce the risk of resistance, with a transition to topical maintenance therapy recommended after an initial course [64]. The rational use of doxycycline, guided by clinical guidelines from organizations such as the and the , is critical to maintaining its efficacy in the face of rising antimicrobial resistance [6].
Side Effects and Safety Profile
Doxycycline, a broad-spectrum of the class, is generally well-tolerated but associated with a range of side effects that vary in frequency and severity. Understanding its safety profile is essential for appropriate clinical use and patient counseling. The most common adverse reactions are gastrointestinal and dermatological, while serious complications, though rare, require prompt recognition and intervention.
Common Side Effects
The most frequently reported side effects of doxycycline are related to the gastrointestinal system and affect approximately 15.7% of patients, with higher incidence in individuals over 50 years of age [66]. These include , , , , and [67]. These symptoms can often be mitigated by taking the medication with a full glass of water and a light meal, although food may slightly reduce absorption [68].
Another prevalent side effect is , a condition where the skin becomes abnormally sensitive to sunlight, leading to reactions resembling sunburn, such as , , and in severe cases, partial-thickness burns or dermatitis [69]. This phototoxic reaction occurs because doxycycline accumulates in the skin and interacts with ultraviolet A (UV-A) radiation [70]. To minimize this risk, patients should avoid direct sun exposure, refrain from using tanning beds, and employ protective measures including broad-spectrum with a high SPF, protective clothing, and sunglasses [71].
Less Common and Serious Adverse Reactions
Less frequently, doxycycline can cause a range of other adverse effects. Skin reactions may include maculopapular or erythematous rashes, and in rare instances, severe hypersensitivity reactions such as , , and anaphylaxis [72]. Gastrointestinal complications can extend to esophageal irritation and , particularly if the tablet is taken without adequate fluid or if the patient lies down immediately after ingestion [62]. To prevent this, patients should take the medication with a full glass of water and remain upright for at least 30 minutes afterward.
Other rare but serious side effects include hepatic dysfunction (elevated liver enzymes, hepatitis), hematological abnormalities such as , , and , and superinfections like or -associated colitis [67]. A particularly severe but rare dermatological reaction is , which requires immediate discontinuation of the drug and emergency medical care [75].
Chronic and Long-Term Effects
Long-term use of doxycycline is associated with specific chronic adverse effects. The most notable is permanent tooth discoloration and enamel hypoplasia, which occurs due to the formation of stable complexes between the drug and calcium in developing teeth and bones [67]. This is the primary reason for its contraindication in children under 8 years of age and in pregnant women after the first trimester [4]. Prolonged therapy may also alter the normal bacterial flora, increasing the risk of superinfections.
In dermatological practice, a distinction is made between anti-inflammatory and bactericidal dosing. Low-dose doxycycline (40 mg/day) is used for its immunomodulatory effects in conditions like , inhibiting and reducing inflammation without significant antimicrobial activity, thereby minimizing the risk of bacterial resistance [58]. In contrast, higher doses (100–200 mg/day) are used for their bactericidal effect in treating moderate to severe and other bacterial infections [2].
Safety in Special Populations and Monitoring
The safety of doxycycline in special populations requires careful consideration. In patients with pre-existing , the drug should be used with caution due to its partial hepatic metabolism and the potential for hepatotoxicity, although dose adjustment is generally not required [21]. In the elderly, increased susceptibility to gastrointestinal and cutaneous side effects, as well as the risk of drug interactions due to polypharmacy, necessitates vigilant monitoring [81].
For patients on long-term therapy for conditions like acne or rosacea, regular outpatient follow-up is crucial. This includes monitoring for clinical response, assessing for adverse effects such as photosensitivity or gastrointestinal upset, and evaluating for signs of superinfection. While routine laboratory monitoring is not typically required for short courses, periodic assessment of , , and is recommended for prolonged use to detect any subclinical organ toxicity [64]. The use of doxycycline as a systemic antibiotic for acne should generally be limited to 3–4 months to minimize the risk of antimicrobial resistance [83].
Contraindications and Special Population Considerations
Doxycycline, a broad-spectrum antibiotic, is contraindicated in specific populations due to significant risks of adverse effects and long-term complications. These contraindications are primarily linked to its mechanism of action involving chelation with calcium ions, which can disrupt the development of bones and teeth, and its potential to exacerbate certain medical conditions [4]. Careful patient assessment is essential before initiating therapy to ensure safety and avoid harm.
Contraindicated Populations
The use of doxycycline is strictly contraindicated in several key groups. It is not recommended for children under 8 years of age because it can cause permanent discoloration of developing teeth and impair bone growth. This occurs due to the formation of stable complexes between the drug and calcium in mineralizing tissues, leading to hypoplasia of the enamel and potential long-term dental issues [26]. Similarly, doxycycline is contraindicated during pregnancy, particularly after the 18th week of gestation, as it can cross the placenta and cause similar developmental problems in the fetus, including tooth discoloration and inhibition of skeletal growth [86]. Its use during lactation is also discouraged because the drug is excreted in breast milk and can adversely affect the nursing infant's bone and dental development [87].
Another absolute contraindication is hypersensitivity to doxycycline, other tetracyclines, or any component of the formulation. Patients with a history of allergic reactions to this class of antibiotics may experience severe adverse events such as anaphylaxis, urticaria, or angioedema [88]. Therefore, a thorough review of the patient's allergy history is mandatory prior to prescription.
Special Considerations for Patients with Comorbidities
Special caution is required when prescribing doxycycline to patients with pre-existing medical conditions. In individuals with severe hepatic impairment, the drug should be used with extreme caution or avoided altogether, as it is partially metabolized by the liver and may increase the risk of hepatotoxicity [89]. Although dose adjustment is generally not required in renal impairment—unlike other tetracyclines such as tetracycline and minocycline—monitoring is still advised, especially in patients with end-stage renal disease or those on dialysis [21].
Patients with lupus erythematosus should avoid doxycycline, as it may exacerbate the disease. Additionally, individuals with a history of idiopathic intracranial hypertension (also known as pseudotumor cerebri) are at increased risk, as doxycycline can induce or worsen this condition, particularly when used concomitantly with systemic retinoids like isotretinoin [4]. This risk is especially relevant in young women and necessitates careful clinical evaluation before treatment initiation.
Considerations for Geriatric and High-Risk Populations
In elderly patients, doxycycline is generally well-tolerated but requires vigilant monitoring due to an increased susceptibility to adverse effects such as gastrointestinal disturbances and photosensitivity [81]. Polypharmacy is common in this population, increasing the likelihood of drug interactions, particularly with anticoagulants like and medications containing divalent cations (e.g., calcium, magnesium, aluminum) that reduce doxycycline absorption [93]. Renal and hepatic function should be assessed before starting treatment, as age-related physiological changes can alter pharmacokinetics.
For travelers and individuals in high-risk groups, doxycycline may be used for prophylaxis against diseases such as and bacterial sexually transmitted infections (STIs), but its use must be balanced against the risk of adverse effects and the potential to drive antimicrobial resistance [3]. In these contexts, patient education on adherence, photoprotection, and the importance of completing the prescribed course is critical to ensure both efficacy and safety.
Drug Interactions and Clinical Precautions
Doxycycline, a broad-spectrum antibiotic, requires careful consideration of drug interactions and clinical precautions to ensure therapeutic efficacy and patient safety. Its pharmacological profile makes it susceptible to interactions that affect absorption, while its use is associated with specific adverse effects and contraindications that must be managed through appropriate clinical guidance. Understanding these factors is essential for optimizing treatment outcomes and minimizing risks in diverse patient populations.
Drug Interactions Affecting Absorption
One of the most significant clinical concerns with doxicycline is its interaction with divalent and trivalent cations, which can severely impair gastrointestinal absorption. Cations such as calcium, magnesium, aluminum, iron, zinc, and bismuth form insoluble chelates with doxicycline in the gastrointestinal tract, reducing its bioavailability by up to 50% or more [2]. This interaction is particularly relevant with products like antiacids, mineral supplements, and dairy products containing calcium [26]. To minimize this effect, doxicycline should be administered at least two hours before or four to six hours after the ingestion of such substances [2]. Although the impact of dietary calcium (e.g., milk, cheese) is considered less pronounced than that of concentrated supplements, it is still advisable to avoid coadministration, especially in severe infections where optimal plasma levels are critical [11].
Interactions with Anticoagulants and Hormonal Contraceptives
Doxycycline may potentiate the effects of oral anticoagulants, particularly , increasing the risk of bleeding. This interaction is thought to occur through two mechanisms: competition for plasma protein binding sites (doxicycline is 75–86% protein-bound) and alteration of gut microbiota, potentially reducing the synthesis of vitamin K by intestinal bacteria [7]. Clinical studies and case reports have documented elevated International Normalized Ratio (INR) values during concomitant use, necessitating frequent INR monitoring and possible warfarin dose adjustments [100]. Patients, especially the elderly or those with unstable INR, should be closely monitored [101].
Historically, there has been concern that doxicycline may reduce the efficacy of hormonal contraceptives, possibly by altering enterohepatic recirculation of estrogens. However, current scientific evidence does not support a significant reduction in serum hormone levels or an increased rate of contraceptive failure [102]. Despite this, many product labels and clinical guidelines continue to recommend the use of an additional barrier method of contraception during doxycycline therapy as a precautionary measure, particularly in high-risk patients [103].
Pharmacological Antagonism and Other Significant Interactions
The concurrent use of doxicycline with bactericidal antibiotics such as may result in pharmacological antagonism. Penicillins require active bacterial replication to exert their lethal effect, while doxicycline, as a bacteriostatic agent, inhibits protein synthesis and bacterial growth. By suppressing bacterial multiplication, doxicycline may reduce the effectiveness of penicillins [2]. This combination should be avoided unless specifically indicated by culture and sensitivity results or in certain prophylactic regimens.
Additionally, concomitant use of doxicycline with other -class antibiotics is not recommended, as it provides no therapeutic advantage and may increase the risk of adverse effects such as hepatotoxicity and gastrointestinal disturbances [4]. The combination of doxicycline with the anesthetic methoxyflurane is associated with severe, potentially fatal nephrotoxicity and should be strictly avoided, especially in patients with compromised renal function [4]. Furthermore, coadministration with systemic retinoids like isotretinoin increases the risk of benign intracranial hypertension (pseudotumor cerebri), a condition characterized by headache, nausea, vomiting, and visual disturbances, particularly in young women [4].
Clinical Precautions and Patient Counseling
Several clinical precautions are essential for the safe use of doxicycline. Patients should be advised to avoid direct sunlight and tanning beds due to the risk of phototoxicity, which can cause severe sunburns, erythema, and skin reactions even with minimal UV exposure [25]. The use of broad-spectrum sunscreen, protective clothing, and avoidance of peak sun hours (10 a.m. to 4 p.m.) is strongly recommended [109]. Alcohol consumption should be limited or avoided, as it may exacerbate hepatic stress and potentially reduce treatment efficacy [2].
To minimize gastrointestinal side effects such as nausea, vomiting, and esophagitis, patients should take doxicycline with a full glass of water and remain upright for at least 30 minutes after ingestion [25]. Taking the medication with light food may help reduce gastric irritation, although this could slightly decrease absorption [62]. Patients with pre-existing renal or hepatic impairment should use doxicycline with caution, as it may exacerbate these conditions, although dose adjustment is generally not required in renal failure due to its biliary excretion [21].
Special Considerations in High-Risk Populations
Patients with a history of should avoid doxicycline, as it may exacerbate the disease [89]. Similarly, individuals with a history of idiopathic intracranial hypertension should be monitored closely, as doxicycline has been associated with increased intracranial pressure [4]. In elderly patients, the risk of adverse effects and drug interactions is heightened due to polypharmacy and age-related changes in organ function, necessitating careful clinical evaluation before initiation [81]. The use of doxicycline in children under 8 years of age, pregnant women, and nursing mothers is contraindicated due to risks of tooth discoloration, impaired bone development, and potential harm to the fetus or infant [4]. However, in life-threatening infections such as anthrax or Rocky Mountain spotted fever, the benefits may outweigh the risks, and use may be justified under strict medical supervision [54].
Role in Tropical and Vector-Borne Diseases
Doxycycline plays a critical role in the management of various tropical and vector-borne diseases, serving as a first-line therapeutic agent for several life-threatening infections. Its broad-spectrum activity, high tissue penetration, and oral bioavailability make it particularly valuable in resource-limited settings and for diseases where rapid intervention is essential to prevent mortality. The drug is recommended by major health authorities, including the and the , for both treatment and prevention of key infectious diseases prevalent in tropical regions [119].
Treatment of Rickettsial Diseases
Doxycycline is the treatment of choice for all forms of , including Brazilian spotted fever (caused by Rickettsia rickettsii), murine typhus, and Q fever. These diseases are transmitted by vectors such as ticks, lice, and mites, and are associated with high morbidity and mortality if not treated promptly. The drug's ability to penetrate host cells—where rickettsiae replicate intracellularly—makes it highly effective [120].
The Brazilian Ministry of Health and the emphasize the importance of initiating doxycycline therapy empirically upon clinical suspicion, even before laboratory confirmation, due to the time-sensitive nature of these infections [121]. The recommended dose is 100 mg every 12 hours, administered orally or intravenously, and continued for at least three days after defervescence, typically for 7 to 10 days [122]. Notably, despite historical contraindications in children under 8 years, current guidelines support its use in severe rickettsial infections in pediatric patients when the benefits outweigh the risks of dental staining [39].
Prophylaxis and Treatment of Leptospirosis
In the context of leptospirosis, a zoonotic disease caused by Leptospira spp. and often associated with flooding and exposure to contaminated water, doxycycline is used both therapeutically and prophylactically. While severe cases typically require parenteral antibiotics such as penicillin or ceftriaxone, doxycycline is effective for mild to moderate disease in adults [124].
Chemoprophylaxis with doxycycline is recommended for individuals at high risk of exposure, such as rescue workers, sanitation teams, and residents in flood-affected areas. The prophylactic regimen consists of a weekly dose of 200 mg orally during periods of risk [60]. This strategy has been implemented in Brazil during natural disasters to reduce the incidence of outbreaks. However, its use must be carefully evaluated to avoid promoting antimicrobial resistance and should be part of a broader public health approach that includes sanitation and rodent control [126].
Management of Sexually Transmitted Infections in High-Risk Populations
Doxycycline is also essential in the management of bacterial such as syphilis, particularly in patients with penicillin allergy. For primary or early syphilis, the recommended regimen is 100 mg twice daily for 14 days [51]. It is also a first-line treatment for chlamydia and lymphogranuloma venereum.
More recently, doxycycline has emerged as a key tool in STI prevention through post-exposure prophylaxis (PEP), known as DoxyPEP. Administered as a single 200 mg dose within 72 hours of condomless sex, DoxyPEP has been shown to significantly reduce the incidence of bacterial STIs—including chlamydia, gonorrhea, and syphilis—among high-risk populations such as men who have sex with men and people living with [3]. The Brazilian Ministry of Health is evaluating its integration into public health programs, balancing its benefits against the potential for increasing antimicrobial resistance [129].
Malaria Prophylaxis in Travelers
For international travelers visiting regions with chloroquine-resistant Plasmodium falciparum, doxycycline is a recommended option for malaria prophylaxis. It is particularly useful in areas of Africa and Southeast Asia where resistance patterns limit the use of other agents [59]. The standard regimen is 100 mg daily, starting 1–2 days before travel, continuing throughout the stay, and for four weeks after departure from the endemic area [48].
However, it is not recommended for use within Brazil, where malaria transmission is focal and controlled through active surveillance and prompt treatment. The Ministry of Health does not endorse chemoprophylaxis for domestic travel, instead prioritizing early diagnosis and therapy [132]. Travelers should receive pre-travel counseling to assess individual risk and select appropriate preventive measures, including non-pharmacological strategies like insect repellent and bed nets [133].
Prophylaxis After Tick Bites
In regions endemic for tick-borne rickettsial diseases, doxycycline is used for post-exposure prophylaxis following tick bites. While not universally recommended, it is indicated when the tick is identified as a known vector (e.g., Amblyomma spp. in Brazil), has been attached for more than 6 hours, and the bite occurs in a high-risk area [119]. A single 200 mg dose within 72 hours of tick removal can prevent the development of Brazilian spotted fever, mirroring the use of doxycycline for Lyme disease prophylaxis in the United States [135]. This targeted approach helps reduce disease incidence without promoting widespread antibiotic use.
Strategic Importance and Public Health Considerations
Doxycycline’s versatility in treating and preventing multiple tropical and vector-borne diseases makes it a cornerstone of public health strategies in endemic regions. Its oral formulation, low cost, and stability in tropical climates enhance its feasibility for use in remote and underserved areas [136]. However, its expanding use—particularly in STI prophylaxis—raises concerns about the emergence of resistance in pathogens such as Neisseria gonorrhoeae and Treponema pallidum [137].
To ensure sustainable use, public health programs must integrate doxycycline into broader initiatives, including surveillance of resistance patterns, provider education, and patient counseling. The implementation of DoxyPEP, for example, should be accompanied by regular STI screening to avoid replacing diagnosis with blanket prophylaxis [3]. By aligning clinical practice with epidemiological data and global health guidelines, doxycycline can continue to serve as a vital tool in the fight against tropical and vector-borne diseases.
Antimicrobial Resistance and Stewardship Strategies
The rise of antimicrobial resistance (AMR) to doxiciclina poses a significant threat to its clinical utility, particularly in the treatment and prevention of bacterial sexually transmitted infections (STIs) and other systemic infections. Resistance arises through multiple genetic and biochemical mechanisms, including efflux pumps, ribosomal protection proteins, and enzymatic modification of the antibiotic. These resistance genes, such as tet(A), tet(B), tet(M), and tet(K), are often carried on mobile genetic elements like plasmids and transposons, enabling rapid horizontal transfer among bacterial populations [139]. The prevalence and dominance of these mechanisms differ between Gram-positive and Gram-negative bacteria. In Gram-positive species like Staphylococcus aureus and Enterococcus spp., ribosomal protection (e.g., Tet(M)) and efflux (e.g., Tet(K)) are primary resistance pathways [140]. In contrast, Gram-negative bacteria such as Escherichia coli and Acinetobacter baumannii rely more heavily on efflux systems (e.g., AcrAB-TolC) and reduced membrane permeability due to altered porins, which collectively create a formidable barrier to the antibiotic's intracellular accumulation [141].
Mechanisms and Surveillance of Resistance
The development of resistance is accelerated by the widespread and sometimes indiscriminate use of doxiciclina, especially in the context of emerging prophylactic strategies like post-exposure prophylaxis for STIs (DoxyPEP). While DoxyPEP has shown significant efficacy in reducing the incidence of bacterial STIs such as chlamydia and syphilis in high-risk populations, its large-scale implementation raises concerns about the selection of resistant strains of Neisseria gonorrhoeae, Treponema pallidum, and Mycoplasma genitalium [3]. The European Centre for Disease Prevention and Control (ECDC) has highlighted this risk, underscoring the need for vigilant monitoring [143]. To combat this, robust surveillance systems are essential. Clinical laboratories perform in vitro susceptibility testing using methods like disk diffusion and minimum inhibitory concentration (MIC) determination. The interpretation of these tests relies on standardized breakpoints established by international bodies such as the Clinical and Laboratory Standards Institute (CLSI) and regional committees like the Brazilian Committee on Antimicrobial Susceptibility Testing (BrCAST) [144]. Continuous monitoring of resistance patterns is crucial for informing local and national treatment guidelines and detecting emerging resistant clones early.
Rational Use and Stewardship Interventions
To preserve the long-term efficacy of doxiciclina, antimicrobial stewardship programs advocate for its rational use based on evidence and clinical guidelines. This involves restricting its use to approved indications, such as rickettsial diseases (e.g., Rocky Mountain spotted fever), Chlamydia trachomatis infections, and atypical pneumonia caused by Mycoplasma pneumoniae, where it is often a first-line therapy [39]. In cases of suspected infection, therapy should be initiated empirically when the clinical and epidemiological context strongly suggests a susceptible pathogen, but should be de-escalated or discontinued based on culture and sensitivity results when possible. The use of doxiciclina as an alternative for multidrug-resistant (MDR) Gram-negative infections, such as those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), is supported by some in vitro data but must be guided by susceptibility testing to avoid treatment failure [146]. Programs like antimicrobial stewardship emphasize the importance of avoiding unnecessary prescriptions, ensuring correct dosing and duration, and educating both healthcare professionals and the public about the dangers of self-medication and incomplete treatment courses.
Strategic Implementation in Public Health
Public health strategies must balance the clear benefits of doxiciclina in preventing and treating serious infections with the imperative to contain resistance. For instance, in tropical and endemic regions, doxiciclina is essential for the early treatment of rickettsioses and for chemoprophylaxis against leptospirosis in disaster scenarios [119]. Its role in malaria prophylaxis for travelers to endemic areas is another critical application [59]. The implementation of DoxyPEP should be selective and targeted to high-risk groups, integrated with regular STI screening and partner notification, and accompanied by rigorous surveillance for resistance [149]. A One Health approach is vital, recognizing that resistance in human pathogens is influenced by antibiotic use in agriculture and veterinary medicine. By adhering to clinical guidelines from organizations like the and the , and by promoting a culture of antibiotic responsibility, the medical community can ensure that doxiciclina remains a valuable tool in the fight against bacterial infections.